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Abstract
Background: We used intensive modern proteomics approaches to identify predictive proteins in ovary cancer. We identify
up-regulated proteins in both serum and peritoneal fluid. To evaluate the overall performance of the approach we track the
behavior of 20 validated markers across these experiments.
Methodology: Mass spectrometry based quantitative proteomics following extensive protein fractionation was used to
compare serum of women with serous ovarian cancer to healthy women and women with benign ovarian tumors.
Quantitation was achieved by isotopically labeling cysteine amino acids. Label-free mass spectrometry was used to compare
peritoneal fluid taken from women with serous ovarian cancer and those with benign tumors. All data were integrated and
annotated based on whether the proteins have been previously validated using antibody-based assays.
Findings: We selected 54 quantified serum proteins and 358 peritoneal fluid proteins whose case-control differences
exceeded a predefined threshold. Seventeen proteins were quantified in both materials and 14 are extracellular. Of 19
validated markers that were identified all were found in cancer peritoneal fluid and a subset of 7 were quantified in serum,
with one of these proteins, IGFBP1, newly validated here.
Conclusion: Proteome profiling applied to symptomatic ovarian cancer cases identifies a large number of up-regulated
serum proteins, many of which are or have been confirmed by immunoassays. The number of currently known validated
markers is highest in peritoneal fluid, but they make up a higher percentage of the proteins observed in both serum and
peritoneal fluid, suggesting that the 10 additional markers in this group may be high quality candidates.
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Introduction
Ovarian cancer (OC) is a leading cause of suffering and death
for women in the United States, and diagnosing it at a pre-
metastatic stage may dramatically reduce mortality. Although OC
accounts for only 4% of all cancer diagnoses in women (National
Cancer Institute. http://www.cancer.gov) it is the most lethal of all
gynecologic cancers. As with many cancers, a woman’s survival [1]
with OC is strongly associated with its stage at diagnosis. Serous
ovarian cancer (SOC) is the most prevalent and deadly histology;
over 70% of all OC cases are diagnosed in a metastatic stage.
Early detection strategies for OC currently under evaluation
have typically involved combining one or more blood-based
markers (typically the marker CA 125) as a means to refer women
to a confirmatory imaging modality such as transvaginal
sonography. When using a marker as a first-line screen, the
performance of the entire screening strategy will be limited by the
performance of this marker and a critically important performance
attribute for an early detection marker is lead-time, i.e. how early
in the disease process the marker elevates. Although preliminary
results suggest that achieving a positive predictive value threshold
of 10% [2] is feasible using the sequential multi-modal approach,
modeling approaches [3–6] and pre-clinical validation studies
profiling CA 125 and other markers [7] suggest that the lead-time
obtained from CA 125 may be insufficient to meaningfully reduce
mortality in a large fraction of women.
Many markers other than CA 125 have been identified and
validated in independent studies using samples collected at the
time of clinical diagnosis [8–18]. We refer to these markers as
‘validated predictive proteins’, by which we mean proteins
confirmed using immunoassays in multiple independent samples
and, therefore, as a group, are likely to be predominantly true
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evaluated in samples obtained prior to diagnosis and suggest that
we can expect few proteins validated in symptomatic disease to
also elevate before symptoms develop [7]. Clearly, improving early
detection for SOC will require identification of new classes of
markers, possibly by plasma or serum proteomic approaches.
One goal of our study includes identifying additional markers
using serum proteomics. However, the feasibility of discovering
differential proteins in serum and plasma has been controversial
and not widely successful, and so a secondary goal of our study is
to validate the overall serum proteome experimental workflow
using several markers as gold standards. In this manuscript we
describe a set of proteomic experiments that interrogate complex
mixtures of human OC biomaterials. The experiments had two
purposes; the first was to identify previously unidentified proteins
that may be additional candidates as predictive markers. The
second was to validate the serum proteomics approach by tracking
the behavior of known validated predictive proteins in order to
establish that the platform is capable of discovering markers. Early
plasma and serum proteome discovery efforts, most often relying
on SELDI or MALDI methods [19–26], have largely failed in this
regard. More recent approaches using tandem MS combined with
intensive fractionation [27–29] might be more appropriate for
serum and plasma biomarker discovery as they have been shown
to identify proteins for pancreatic cancer [30] that have been
subsequently validated. However, because the success of any
discovery approach will certainly depend on the disease charac-
teristics as much as the technology, prior to investing resources
into developing antibodies for new markers, we first wished to
confirm that the approach is capable of producing reproducible
results.
We have interrogated both a circulating fluid, serum, and a fluid
proximal to the tumor, ascitic fluid or peritoneal fluid from control
patients with benign serous tumors (BST). We conducted two
different experiments on serum: the first experiment compared
serum pools from metastatic SOC patients to pools from matched
healthy asymptomatic volunteers; the second experiment com-
pared serum pools from a different set of metastatic SOC patients
to serum pools from women with BST. For the proximal fluid
experiments, we compared pools of ascitic fluid from metastatic
SOC patients to pools of peritoneal fluid from patients with BST.
In all experiments, samples were matched based on age, storage
duration, hormone replacement therapy use and time of collection
prior to surgery (for case/control comparison). By combining these
data sets and identifying proteins that appear to be up-regulated in
SOC in both serum and fluid proximal to the tumor, we hope to
enrich our potential candidate list with cancer-specific markers.
Results
Annotation of proteins based on existing data resources
A list of 21 proteins previously shown to be up-regulated in
plasma or serum of SOC compared to healthy control by ELISA
assays was compiled by examining the OC biomarker literature.
We identified these proteins as well as one additional protein,
IGFBP1, discovered and validated in this work as true positive
controls. Four of the true positive proteins were not identified in
either plasma or peritoneal fluid: MUC16 [31–33], TNFRSF6B
[14], VTCN1 [14,17] (aliases CA 125, DcR3, B7-H4, respectively)
and VEGF [16]. Table 1 lists the 19 true positive proteins that
were identified in plasma or peritoneal fluid [14,16,17,31–33]. All
of them were observed and quantified in peritoneal fluid, and 7
were observed in plasma; no positive controls were identified
exclusively in plasma.
Serum comparisons
The serum proteomics experiments (described below) compared
metastatic serous ovarian cancer (SOC) to either healthy
asymptomatic (HA) women or women with benign serous tumors
(BST). Table 2 shows the total number of quantified proteins in
each serum experiment. Over 360 proteins were quantified in each
experiment and a total of 470 proteins were quantified in at least
one or the other experiment. Collapsing these proteins by gene
symbol results in slightly lower totals due to different isoforms
identified for the same gene. In Figure 1, the association between
log2 ratios for all quantified proteins by gene symbol for the two
serum experiments is plotted (horizontal and vertical axis reflect
SOC versus HA and SOC versus BST, respectively). Note that all
ratios are oriented so that a positive value implies a protein ratio
higher in SOC. Proteins that were not observed in one experiment
are represented by a pseudo ratio of ‘1’ (log2=0) for that
experiment.
Figure 1 reveals a promising pattern that one can expect to see
in an experiment that compares two complex mixtures and in
which some differential proteins are observed: most proteins fall
near the origin and vary in an uncorrelated manner since no
systematic changes are occurring but a number of them in the
upper right quadrant trend away from the bulk. For the purpose of
characterizing our results, we label a protein as up-regulated if its
consensus ratio meets or exceeds a 2-fold change (i.e, log2 (SOC/
HA)+log2(SOC/BST)$1 as indicated by the line in Figure 1). All
54 proteins meeting this criterion are shown in green if observed in
both comparisons or blue if observed in only one. These proteins
are also listed in Table S1 (in supplementary information).
Those proteins that correspond to our ‘benchmark’ proteins
from Table 1 are denoted with an asterisk. A total of seven
benchmark proteins were observed in serum including six that
were previously validated as well as one additional marker,
IGFBP1, denoted with a double asterisk, which we validated here
based on these experiments. All seven of the observed benchmark
proteins were up-regulated by our criteria. The observed
enrichment (7 of 7) is highly significant (p-value=1e-6), demon-
strating that our serum proteomic analysis finds high concordance
with validated assays.
Peritoneal fluid experiments
The peritoneal fluid experiments are compared using a label-
free method that allows us to quantify all observed proteins, not
only those containing an isotopically labeled cysteine amino acid.
After collapsing by gene symbol, 2950 proteins are observed in
both experiments. The comparison of log2(peptide spectral counts)
between SOC to BST is plotted in Figure 2. For convenience,
proteins with spectral count=0 in one fluid but are observed in the
other fluid are set to 0.5. We define a protein as up-regulated if it
has an SOC peptide count at least two-fold higher than the
corresponding BST peptide count. From the 2950 identified
proteins by gene symbol, 358 are selected as potentially up-
regulated based on this criterion (see Table S1). Proteins that were
also found up-regulated in the serum experiments are shown in
red. We also annotate those proteins reported by Kuk et al [34]
who evaluated SOC ascitic fluid. In our experiments, 73 of the
Kuk candidates are observed, shown in blue in Figure 2, and are
distributed widely among SOC and BST counts with only 37 up-
regulated. Kuk et al did not evaluate material from BST. As in the
serum experiments, we found a significant enrichment of validated
biomarkers among the up-regulated proteins in ascitic fluid. Of the
19 benchmark proteins observed in either peritoneal fluid (labeled
in Figure 2), all but two, MIF and MSLN, were up-regulated (p-
value=2e-16). Note that MIF up-regulation is possibly associated
Ovarian Cancer Proteomics
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with the conclusions of Kuk et al. that cancer ascitic fluid may be a
valuable resource for identifying biomarker candidates, although
our results from the BST suggest that many of them will not be
cancer specific.
Comparison of serum versus peritoneal fluid
To compare the two different types of fluid, the consensus log2
ratios over both serum experiments were plotted against the log2
ratio of SOC ascitic fluid over BST peritoneal fluid, as shown in
Figure 3. Because only proteins observed in both materials can be
plotted, this comparison includes only those 358 proteins observed
in both serum and peritoneal fluid. A total of 17 of these proteins
were designated as up-regulated in both sets. The overall
concordance of all proteins, as measured by the correlation in
the ratios, is not strong, but this is not unexpected since most
proteins are not changing between the two sources and for those
experimental sources of variation should dominate. Only among
proteins that systematically vary between case and control should
we find concordance. The 17 proteins that are up-regulated in
both experiments (listed in Table 3 and shown in blue in Figure 3)
are highly enriched for the validated biomarkers listed in Table 1.
All seven observed benchmark proteins measured in both
experiments were found up-regulated (p-value=2e-16). However,
the greatest benefit we observe by using the overlap of the two
experiments is a substantial increase the percentage of validated
markers among all up-regulated markers. In serum, 15% of the
up-regulated proteins were benchmark proteins and in the ascitic
fluid candidate list, 5% were benchmark proteins. If we use the
overlap of those two experiments, the percentage of candidate
proteins from the validated benchmark list increases to 7 out of 17
(41%).
Table 1. Summary of performance of true positive ‘‘benchmark serum proteins.
gene symbol alias ref
a log2 (SOC/HA)
b log2 (SOC/BTS)
c
SOC pert.
fluid
d
BST pert.
fluid
e
mean serum
ratio
f
pert. fluid
ratio
g
CHI3L1 [33] 69 5 13.8
ENPP2 LPA, ATX [8] 108 21 5.1
IGFBP2 [10] 1.42 0.60 133 36 2.02 3.7
KLK10 [11] 6 0 6.0
KLK11 hk11 [12] 13 3 4.3
KLK5 [11] 2 0 2.0
KLK6 [11] 41 1 41.0
KLK7 [11] 3 0 3.0
KLK8 [11] 8 0 8.0
LCN2 [33,47] 1.11 0.06 57 6 1.50 9.5
MIF [33,48] 56 117 0.5
MMP7 [33] 1.42 10 0 2.68 20.0
MSLN [32,33] 45 33 1.4
SLPI [13] 0.23 1.20 5 0 1.64 10.0
SPON2 [14] 9 0 9.0
SPP1 OPN [33,49] 24 2 12.0
TIMP1 [15] 0.59 0.80 73 24 1.62 3.0
WFDC2 He4 [18] 1.27 2.67 22 3 3.93 7.3
IGFBP1 1.89 2.41 11 0 4.45 22.0
Proteins that have been previously shown to be up-regulated in serum or serum of SOC cases compared to HA controls by ELISA assays, or (for IGFBP1) shown for the
first time here.
a) literature citing assay results.
b) log2 transformed IPAS ratio SOC/HA.
c) log2 transformed IPAS ratio SOC/BST.
d) peptide counts from SOC peritoneal ascitic fluid.
e) peptide counts from BST peritoneal fluid.
f) geometric mean of ratio measured in two IPAS experiments.
g) ratio of SOC peritoneal fluid counts to BST peritoneal fluid counts.
doi:10.1371/journal.pone.0011137.t001
Table 2. Summary of proteins quantified in each experiment.
Experiment
Quantified Protein
Groups
Quantified Gene
Symbols
Serum
SOC v HA 362 331
SOC v BST 374 332
Combined 470 416
Peritoneal fluid
SOC 1788 1609
BST 2810 2603
Combined 3239 2950
Serum experiments count only those proteins for which a cysteine containing
peptide was observed. Peritoneal fluid experiments count all proteins observed.
doi:10.1371/journal.pone.0011137.t002
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annotation for two GO categories, extracellular region and
inflammatory or response to wounding where a ‘‘yes’’ indicates
the protein is annotated for that term either at the leaf or a parent
node. The ‘‘extracellular region’’ term indicates that protein is
located outside the plasma membrane and could be secreted into
blood. Among the 17 proteins, 14 (82%) of them are annotated as
extracellular compared to 17% of all proteins observed in the
experiments. This disproportion supports the hypothesis that by
combining data from circulating and proximal fluids we might be
more likely to discover protein biomarkers secreted or shed from
the tumor rather than deriving elsewhere in the host. We have also
included GO terms related to inflammation in this table to rule out
proteins that may not be cancer-specific. Only two of the 17
overlap proteins are known to be involved in inflammation.
ELISA validation of IGFBP1
The validation status of all 17 candidate proteins is indicated in
Table 3. Commercial ELISA assays are available for 8 of the 17
proteins. Of those, six were validated in previous studies (see
Table 1). The remaining two proteins derived from this study,
MMP9 and IGFBP1, were assayed in this study.
Validation was performed in three stages. In the first stage, the
markers were tested in a series of mixtures of varying ratios of
pooled sera from OC patients and pooled sera from HA controls
from the filtering set of samples (50 OC, 9 HA controls) described
in Methods. Both proteins had high concentrations in the high OC
pool but only IGFBP1 showed a concentration dependence with
the ratio of ovarian cancer sera to control. Both proteins were then
tested against individual samples from the filtering set (12 OC, 12
HA controls) described in Methods. IGFBP1 levels were
significantly higher in cancer serum (p-value=0.0097) while
MMP9 levels were not (p-value=0.20). A third set of samples
that was restricted to serous ovarian cancer cases (44 SOC, 78 HA
controls) was used to confirm the elevation of IGFBP1. In this data
set, the significance of case to control difference increased to 5.0e-4
and the ROC curve had an AUC of 0.860. The ROC curve for
these samples shown in Figure 4 demonstrates the ability of
IGFBP1 to classify OC versus HA and BST controls, showing
results consistent with the behavior in the proteomics experiments.
Figure 2. Comparison of peptide counts from peritoneal fluid
experiments. Red points are up-regulated in SOC serum. Blue points
are proteins observed in ovarian cancer ascitic fluid by Kuk et al [34].
Benchmark proteins are labeled. Points above green dashed line are
considered up-regulated in peritoneal fluid.
doi:10.1371/journal.pone.0011137.g002
Figure 1. Log2 serum protein ratios from both IPAS experi-
ments. Green points represent proteins up-regulated in both
experiments. Blue points represent proteins up-regulated in one
experiment and not observed in the other. *Benchmark marker
validated by ELISA assay; **New marker validated by ELISA assay.
doi:10.1371/journal.pone.0011137.g001
Figure 3. Comparison by log2 ratio of serum to peritoneal
ascites fluid. Proteins up-regulated in both fluids are colored blue.
*Benchmark marker validated by ELISA assay; **New marker validated
by ELISA assay.
doi:10.1371/journal.pone.0011137.g003
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Proteomic profiling of serum or plasma to discover cancer
biomarkers has not yet met with widely demonstrated success [19–
26] where the proteins were validated in independent samples or
using independent platforms. One notable exception is a
pancreatic cancer study using a mouse model and in-depth
fractionation of intact proteins [30]. In this manuscript we have
used a similar approach for tandem MS proteomic profiling of
serum in combination with profiling of peritoneal fluid as proximal
tumor fluid. We have produced a short list of 17 biomarkers found
up regulated in both serum and proximal fluid – that include 7
proteins that have been validated using existing ELISA assays,
including a new SOC biomarker (IGFBP1). The remaining 10
markers in this group may represent high quality candidates.
Our success in identifying many validated markers may have
resulted from a number of features in the experimental design.
Sample bias was eliminated by careful sample collection and
tightly matching cases to controls. In addition to matching based
on age, race and family history of OC, controls were also matched
on HRT use and number of days prior to surgery at blood draw.
HRT has been shown to dramatically affect the levels of many
serum proteins [35,36]. Thorpe et al [37] demonstrated that blood
drawn the day of surgery is associated with the elevation of several
serum proteins. This bias was avoided here by careful sample
matching based on case/control collection condition. Another
important aspect this analysis was the use of extensive sample
fractionation prior to MS. This design, which has been shown to
obtain sensitivities of 10ng/ml concentration [35,36], allowed
greater depth of proteome coverage by tandem MS to identify
potentially meaningful changes.
An important aspect of the design of the serum experiments was
the use of three different types of subjects: ovarian cancer patients,
healthy asymptomatic volunteers and patients with benign tumors.
Proteins up-regulated in SOC relative to HA but not relative to
BST are not likely to be cancer-specific and were eliminated from
consideration. The same was true of proteins up-regulated relative
to BST but not to HA. Using only the SOC vs BST comparison,
we would have found 5 out of 7 quantified validated markers as
opposed to 7 out of 7 (TIMP1 and SLPI would be removed).
Combining the serum data with data from proteomic profiling
of peritoneal ascitic fluid allowed us to identify a group of proteins
have a large fraction of our true positive proteins; eliminating
Table 3. Proteins up-regulated in both serum and peritoneal fluid.
genes
log2
SOC/HA
log2
SOC/BST
SOC pert.
fluid
spectral
count
BST perit.
fluid
spectral
count
mean
serum
ratio
pert. fluid
SOC/BST
ratio
GO
extracellular
GO
inflammatory/
response to
wounding
assay
availability
validated by
ELISA
CFHR4 1.55 19 7 2.92 2.71 yes
CFHR5 0.93 0.35 105 47 1.56 2.23 yes
GOLM1 1.01 0.49 62 10 1.69 6.20
HAVCR2 0.76 0.75 12 3 1.69 4.00
IGFBP1 1.89 2.41 11 0 4.45 22.00 yes yes yes
IGFBP2 1.42 0.60 133 36 2.02 3.69 yes yes yes
LCN2 1.11 0.06 57 6 1.50 9.50 yes yes yes
LRG1 2.76 1.90 173 24 5.03 7.21 yes
MMP7 1.42 10 0 2.68 20.00 yes yes yes
MMP9 1.00 11 4 2.00 2.75 yes yes no
ORM1 1.44 0.30 2970 879 1.83 3.38 yes yes
SERPINA3 1.17 0.56 974 378 1.83 2.58 yes yes
SLPI 0.23 1.20 5 0 1.64 10.00 yes yes yes
SPINK1 2.90 8 1 7.44 8.00 yes
TIMD4 1.24 2 0 2.36 4.00
TIMP1 0.59 0.80 73 24 1.62 3.04 yes yes yes
WFDC2 1.27 2.67 22 3 3.93 7.33 yes yes yes
doi:10.1371/journal.pone.0011137.t003
Figure 4. IGFBP1 ROC curves. SOC vs HA is shown in black and SOC
vs BST in blue.
doi:10.1371/journal.pone.0011137.g004
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candidates from 54 to 17 while retaining all seven benchmark
proteins quantified in serum. This result supports the hypothesis
that proteins identified in a fluid proximal to the tumor and also in
a circulating fluid will identify effective biomarkers. Kuk et al [34]
showed that ascitic fluid from patients with ovarian cancer
contained a large number of high quality markers, and our results
are concordant with those findings. However, because the number
of benchmark proteins found in peritoneal fluid is higher than
found in serum, one cannot make the claim that more markers can
be identified by requiring observations in both serum and
proximal fluid. Indeed our data and that from Kuk et al. suggest
that ascitic fluid proteomics data may contain the greater number
of high quality markers. Our findings suggest only that requiring
proteins to be observed in both samples could lead to a greater
proportion of high quality markers. This hypothesis cannot be
confirmed, however, without also systematically evaluating true
negative markers as well as true positives. Moreover, not
identifying all known markers does not indicate that the marker
is not of high quality nor that the process is necessarily at fault. For
example, our platform was not able to identify CA 125 nor three
other markers that we initially selected as benchmark proteins,
possibly due to sensitivity limitations on mass spectrometry.
However, given that a platform is able to quantify existing
validated markers, one would find concordance between the two
platforms reassuring, which we found here.
In their combined data from four different fractionation
methods Kruk et al. identified 445 proteins total, a number
considerably lower than the thousands of protein groups we
observed in our experiments. This difference is partly due to their
focus on the subproteome of proteins less than 100 kDa as our set
includes 490 proteins larger than 100kDa. But the use of intensive
fractionation may account for the remaining disparity. Despite
these differences, the conclusions of their study are highly
consistent with our findings; after applying some data mining
techniques, they reduced their candidate list to 77 proteins
(including 25 known OC markers), 73 of which were observed in
our study. As apparent in Figure 2, the relative abundances of the
Kuk proteins include some that are up as well as down; only half of
these are up by two-fold relative to the benign peritoneal fluid. Of
the 19 benchmark proteins observed in either pool of peritoneal
fluid, 17 have spectral counts two-fold higher in SOC than BST.
This suggests that although Kuk et al were correct in their assertion
that ascitic fluid is a rich source of potential markers, our work
suggests that the inclusion of a control material can be helpful in
reducing false positives. One of the strengths of this study is the use
of relative abundances of SOC to BST to find proteins specific to
malignant disease.
The issue of confounding inflammatory proteins (recently
addressed by Checlinska et al [38]) is minimized in multiple ways
in our study. First, our depletion and fractionation methods allow
us access to proteins beyond just the highly abundant ones that
often include many proteins related to inflammation. Additionally,
our comparisons between cancer and benign disease filter out
many proteins that elevate due the presence of a benign tumor;
inflammatory proteins shared by both conditions are eliminated.
Also, since we are targeting secreted proteins by looking for
overlap between proteins in the proximal fluid and those elevated
in serum, we will reduce the possibility of observing serum proteins
synthesized in the liver as an inflammatory response. Still, Table 3
includes two proteins (ORM1, SERPINA3) out of 17 biomarker
candidates that have roles in inflammation. While we have greatly
improved the proportion of biomarkers related to inflammation
over previous profiling experiments [39,40], we can not com-
pletely remove all confounding factors and must rely on
annotation when available for furthering filtering.
In this work we have also discovered and validated a novel
biomarker for symptomatic serous ovarian cancer, insulin
growth factor binding protein 1. Like IGFBP2, IGFBP1 is a
member of the insulin-like growth factor binding protein family
and binds both insulin-like growth factors, IGF1 and IGF2. Like
the other IGFBPs, IGFBP1 is expressed in local tissues,
including ovary, and is present in normal plasma. Serum levels
of IGFBP1 are significantly decreased in post-menopausal
women taking hormone replacement therapy [35]. Though
elevated serum levels of IGFBP2 have been demonstrated in a
number of cancers, including ovarian [10], this is the first
evidence that IGFBP1 levels increase in serum or plasma of
patients with ovarian cancer. One other study showed elevated
levels of IGFBP1 (and IGFBP2) in plasma of patients with head
and neck cancers [41].
Finally, we also note that among the 17 markers shown to be
up-regulated in the serum and ascitic fluid of SOC, all but three
are secreted proteins. Although it is routinely claimed that secreted
proteins should be preferred as candidates due to their potential to
secrete into the blood, this claim is not often supported
empirically. Our data provide a strong support for this generally
accepted hypothesis.
As described in the introduction of this manuscript, though
several serum biomarkers for ovarian cancer have been discovered
and validated, all of the markers have shown poor performance in
pre-diagnostic samples. In this study, we set out to establish the
capability of proteomic profiling of serum to discover ovarian
cancer biomarkers when used in conjunction with other profiling
of proximal fluid. Having demonstrated the success of this
approach, we can now confidently apply these methods to more
challenging pre-symptomatic samples.
Materials and Methods
Recruitment and collection of human blood and
peritoneal fluid for discovery
All research for this study was specifically conducted under Fred
Hutchinson Cancer Research Center Institutional Review Board
approved protocols, IR# 6045 and IR# 6094. All human samples
were derived from subjects who provided written consent. Data
were analyzed anonymously.
Serum from women with serous ovarian cancer (SOC), benign
serous tumors (BST), and from healthy asymptomatic (HA)
controls was used in our proteomic discovery and validation
experiments. Sample collection protocols have been previously
described in detail elsewhere [32,37]. In brief, serum and
peritoneal fluid from women with SOC and BST were collected
prior to surgery and chemotherapy as part of an Ovarian Cancer
Specialized Program of Research Excellence (SPORE) funded by
the National Cancer Institute. Diagnosis of SOC and BST were
confirmed by central pathology review. Age and hormone
replacement therapy (HRT) matched HA controls were recruited
through an ovarian cancer screening program, where all patients
represent asymptomatic controls. All serum samples, regardless of
the collection source, were processed with the same protocol;
blood was collected in 10cc Vacutainer Serum Separator Tubes
(SST) and allowed to sit for 30 minutes to 4 hours at room
temperature. The tubes were centrifuged at 1200-6g for
10 minutes, then split into multiple 1-ml aliquots of serum and
stored at 280 degrees Celsius. Prior to use, each 1-ml vial of serum
was thawed on ice, split into multiple 110-microliter subaliquots,
and stored back at 280 degrees Celsius.
Ovarian Cancer Proteomics
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container in the operating room by surgical staff. Using a sterile
1cc syringe, 20,000 units of heparin (vials contain 10,000 units per
cc) was added to each liter of fluid to prevent the formation of
blood clots. In the lab, the fluid was transferred to conical
centrifuge tubes (50cc or 250cc depending on fluid volume) and
spun in a balanced centrifuge at 2000 rpm for 5 minutes to pellet
the cellular component. Cell-free supernatant was transferred to
one 50cc conical tube and five 1.5 ml microcentrifuge tubes for
storage at 280 freezer degrees Celsius.
Selection of specimens for discovery experiments
Only post-menopausal women having average risk of ovarian or
breast cancer were included (average risk implies no significant
family history of breast or ovarian cancer and no previous cancer
diagnosis) in the discovery experiments. The first serum discovery
experiment compared women with late stage SOC to HA controls
and the second compared to women with BST. SOC pools of size
4 (to healthy controls) and size 5 (to BST) were selected to be
tightly matched to controls based on age (+/22 years), sample
storage time (+/21 year) and HRT [35]. Moreover, because
collection environment has a known effect on serum proteome
[37], cases and controls were also matched based on whether the
blood collection occurred the day of surgery (for SOC versus BST
controls) or whether they were collected three or more days prior
to surgery (for SOC versus HA controls). For the peritoneal fluid
experiments, a pool of size 10 SOC samples was compared to a
pool of size 4 BST samples. The pool size for BST is smaller
because, while a large fraction of SOC patients develop ascites,
few BST patients produce comparable ascitic fluid.
Selection of serum samples for validation experiments
Experiments to validate the proteins were performed for two
markers in three previously described [32,33] sets of serum
specimens. These sets included two filtering sets. The first set was
composed of pooled samples from 50 OC patients (case pool) serially
diluted with serum from 9 HA controls (control pool). The second set
was comprised of individual samples from 12 OC patients and 12 HA
controls. A third larger set of individual samples was used to confirm
proteins that showed significant elevation in the second set. This set
was restricted to serous ovarian cancer cases and included 44 SOC
patients and 78 HA controls, representing a subset of those sampled
described by Palmer et al [33].
Sample processing of serum for discovery experiments
In each case/control comparison serum was depleted of the
seven most abundant proteins and quantitatively compared using
isotopically labeled acrylamide [29] following extensive off-line
separation of intact proteins. This method is referred to as the
Intact Protein Analysis System (IPAS) protocol [28]. In brief, case
and control pools were separately depleted of abundant human
proteins using two Multiple Affinity Removal System (MARS)-7
high capacity columns (Agilent, Santa Clara, CA) coupled serially
on a Shimadzu HPLC system following the manufacturer’s
protocol. Depleted samples were concentrated using Amicon-15
and Amicon-4 concentrators (Millipore, Billerica, MA) down to
100–250 ul then diluted to 0.5–0.8 ml in labeling buffer (8 M
urea, 100 mM Tris pH 8.5, 0.5% octyl-beta-d-glucopyranoside
(w/v)). A standard Bradford assay was performed to determine
protein concentration. The samples were reduced by addition of
0.66 mg of dithiotreitol per 1 mg of protein, then incubated at
room temperature for 2 hours. Samples were alklyated with
acrylamide (light label) (Sigma-Aldrich, St. Louis, MO) or C13-
acrylamide (heavy label) (Cambridge Isotope Laboratories, And-
over, MA) by addition of 7.1 mg/mg protein of acrylamide or
7.4 mg/mg protein of C13-acrylamide per 1 mg of protein, then
incubated in the dark at room temperature for 1 hour. Samples
labeled with acrylamide were mixed with samples labeled with
C13-acrylamide, and immediately filtered with a low protein-
binding filter. In the SOC/HA serum comparison, the case pool
was labeled with heavy acrylamide and control pool light
acrylamide. In the SOC/BST serum comparison, the label
orientation was reverse so that the case pool (SOC) had the light
label. The change in label orientation was used to avoid any label
bias and to serve as a means to help filter out bad identifications
by selecting peptides that are observed in both heavy and light
forms.
The combined mixture was subjected to an automated online
2D-HPLC system described by Piterri et al [42]. Briefly, using the
Workstation Class-VP 7.4 (Shimadzu Corporation), the labeled
serum was separated in the first dimension on an anion exchange
column (Poros HQ/10, 10 mm i.d.6100 mm l, Applied Biosys-
tems) using an 8 step-elution (from 0 to 1000 mM NaCl) at
0.8 mL/min. Fractions from each of the 8 anion-exchange
separation elution steps were automatically transferred onto a
reversed-phase column (PorosR2/10, 4.6 mm i.d.6100 mm l,
Applied Biosystems) for second dimension of separation in to 84
fractions for every anion-exchange fraction. A 25 min gradient
elution (from 5% to 95% mobile phase B) was used at 2.4 mL/
min. Mobile phase A for anion-exchange chromatography
consisted of 20 mM Tris (Sigma), 6% isopropanol (Fisher), and
4 M Urea, pH 8.5, and mobile phase B was the same
composition and pH as mobile phase A with 1 M NaCl (Fisher)
added. Mobile phase A for reversed-phase chromatography
consisted of 95% water, 5% acetonitrile, and 0.1% TFA
(Supelco), and mobile phase B consisted of 90% acetonitrile,
10% water, and 0.1% TFA.
The resulting 672 aliquots were lyophilized and resuspended in
0.25 M urea (Fisher) containing 50 mM ammonium bicarbonate
and 4% acetonitrile and then digested overnight with 200 ng of
modified trypsin (Promega). The digestion was interrupted by
addition of 5 mL of 10% formic acid solution. Digestion was
carried out overnight at 37uC. The resulting peptide mixtures
were acidified with 5 mL of 1% formic acid. Each set of 84 reverse
phase fractions was pooled to 12, resulting in 96 fractions total.
Processing peritoneal fluid
Case and control peritoneal fluid were compared using a label-
free approach rather than by isotopic labeling. Each case and
control pool was separately depleted of the seven highest abundant
serum proteins using two MARS-7 columns as above. As with
serum, two dimensions of fractionation were used. First intact
proteins were separated into 12 fractions by reversed phase then
each fraction was digested prior to a second orthogonal separation
using isoelectric focusing. Specifically, digested reversed-phase
separated fractions of cancer and benign peritoneal fluid were
each combined into six pools of approximately 330 mg peptide per
pool. Each pool was desalted on a C18 column (Waters, Milford,
MA), eluted in 80% acetonitrile in acidified water, and dried
under reduced pressure. Each pool was individually prepared for
separation by isoelectric focusing using the Agilent 3100 OFF-
GEL Fractionator per the manufacturer’s protocol. Briefly, each
dried peptide sample was resuspended in a solution containing
OFF-GEL sample buffer and pH 3–10 ampholytes (Agilent), and
divided into 24 wells over a rehydrated immobilized pH 3–10
gradient gel (Agilent). With cancer and benign samples on
independent sample trays, pools were simultaneously focused for
33 hours until the accumulation of ,56 kVh. Focused fractions
Ovarian Cancer Proteomics
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of the 12 original pools. The digested sample was desalted on a
Grace (Deerfield, IL) Vydac UltraMicroSpin C18 cartridge and
dried prior to mass spectrometric analysis.
Mass spectrometry acquisition
Each fraction was analyzed for each experiment by a LTQ-
Orbitrap (Thermo) mass spectrometer coupled with a NanoLC-
1D (Eksigent). The liquid chromatography separation was
performed in a 25 cm column (Picofrit 75 mm i.d., New
Objectives, packed in-house with MagicC18 resin) using a
90 min linear gradient from 5 to 40% of acetonitrile in 0.1%
formic acid at 300 nL/min for shotgun analysis. Spectra were
acquired in a data-dependent mode in m/z range of 400–1800,
including selection of the 5 most abundant +2o r+3 ions of each
MS spectrum for MS/MS analysis. Mass spectrometer parameters
were capillary voltage of 2.0 kV, capillary temperature of 200uC,
resolution of 60 000, and target value of 1 000 000.
Mass spectrometry interrogation and data processing to
Identify and quantify proteins and to aligning results
from experiments
The acquired LC-MS/MS data were searched against the human
International Protein Index (IPI) version 3.48 using the Mascot
search engine. For the labeled serum experiments, cysteine alkylation
with the light form of acrylamide was set as a fixed modification and
with the heavy form of acrylamide (+3.01884) as a variable
modification. PeptideProphet [43] was used to evaluate each peptide
assignment and ProteinProphet [44] was used to group peptides into
protein groups, but only peptides having PeptideProphet probability
.0.95 were used in the ProteinProphet inference (i.e., in contrast to
the default configuration in ProteinProphet, we omitted moderately
confident peptides due to the dramatic inflation of ProteinProphet
rates that results from their inclusion [45]). Contaminant proteins
were removed from the data set including those targeted for
depletion, byproducts of coagulation or deleted from more recent
IPI database releases. Relative quantitation was performed using the
Q3 algorithm [29]. Peptides with zero area were reset to a
background value to avoid singularities. Only highly confident
peptide identifications – those having PeptideProphet probability
$0.95, mass deviation ,20 ppm and more than one scan – were
used whencomputing protein ratios.Protein ratios were calculated by
taking the geometric mean of all the associated peptide ratios for a
protein group. Protein group ratios were logarithmically transformed
and median-centered at zero. To quantify proteins from the
peritoneal fluid experiments, total protein spectral count was used
as a surrogate quantitative measure using only highly confident
peptide identifications. In order to avoid singularities when
computing ratios for the peritoneal fluid experiments, 0.5 as added
to proteins with zero spectral counts in one fluid and nonzero counts
in the other.
For each fluid, proteins from the two experiments were grouped
using a previously described algorithm [46] so that each protein
group contains one or more protein sequences indistinguishable
based on the peptide evidence and consistent across experiments.
Gene symbols were then assigned to each member of a protein
group using IPI protein cross-reference and the protein groups
were collapsed to a single gene symbol using the geometric mean
for IPAS ratios and the maximum peptide counts for peritoneal
fluid experiments. The serum and peritoneal fluid data sets were
integrated by matching gene symbols.
ELISA validation
Serum samples were screened for IGFBP1 and MMP9. IGFBP1
was evaluated using a DuoSetH ELISA development system from
R&D Systems (Minneapolis, MN) according to the package
directions. Briefly, the capture antibody was coated on an ELISA
plate at 4 mg/ml in PBS overnight at room temperature. The wells
were rinsed three times with wash buffer (0.05% Tween 20 in PBS)
and blocked for 1 hour with blocking buffer (5% Tween 20 in PBS).
The wells were washed again according to the previous directions. A
standard curve was made in blocking buffer and serum samples were
also diluted 1:100 in blocking buffer. These samples were added to
the plate in duplicate and allowed to incubate for 2 hours at room
temperature. The wells were washed again and the detection
antibody was added to the wells at 400 ng/ml. This was allowed to
incubate for 2 hours and the wells were once again washed.
Streptavidin-HRP was added and allowed to incubate for 20 minutes
before the solution was removed and the wells washed. In order to
develop the assay, TMB One Solution (Promega Corporation,
Madison, WI) was added to the wells and allowed to incubate in the
dark for 20 minutes before the reaction was stopped with an equal
volume of 1N Sulfuric Acid (Acros, New Jersey). The optical density
was determined using a microplate reader set to 450 nm. MMP9 was
evaluated using the Human MMP-9 ELISA Kit from RayBiotech
Inc. (Norcross, GA) according to the kit directions. Briefly, samples
were diluted 1:5000 and added along with standards to the plate
precoated with the capture antibody. This was incubated for
2.5 hours at room temperature and then the wells were washed with
Wash Buffer provided in the kit. The biotinylated detection antibody
was added to the wells and incubated for 1 hour at room
temperature. The wells were again washed with Wash Buffer and
Streptavididn-HRP was added to the wells for 45 minutes. The wells
were washed one final time and TMB One-Step Substrate Reagent
was added to the wells and allowed to incubate for 30 minutes. The
reaction was terminated by adding Stop Solution to the wells and the
optical density was determined using a microplate reader set to
450 nm.
Supporting Information
Table S1 Proteins up-regulated in either SOC peritoneal fluid
or SOC serum.
Found at: doi:10.1371/journal.pone.0011137.s001 (0.01 MB
TXT)
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